GlassScriptPhysician profile
Alan H Yamada
NPI 1760456040
$12,864.23
in general payments reported to CMS, 2019-2025
44 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,295 · 2020: $545 · 2021: $978 · 2022: $2,672 · 2023: $2,355 · 2024: $1,807 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,631 · Travel and Lodging: $460 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,631.23 |
| Travel and Lodging | $459.96 |
| Education | $282.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $2,311.12 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $1,208.18 | 2019-2024 | Xtandi, Myrbetriq |
| Neotract INC. | $1,073.03 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $861.98 | 2022-2025 | Prolaris, Myrisk |
| Abbvie INC. | $814.94 | 2021-2025 | Botox |
| Procept Biorobotics Corporation | $795.66 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Sumitomo Pharma America, INC. | $654.70 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $639.12 | 2019-2025 | Erleada, Akeega |
| Pfizer INC. | $590.46 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $586.58 | 2019-2025 | |
| Progenics Pharmaceuticals, INC. | $349.36 | 2021-2025 | Pylarify |
| Myovant Sciences INC. | $238.30 | 2021-2022 | |
| Boston Scientific Corporation | $229.92 | 2019-2023 | Lithovue, Spaceoar Vue System - 10ml |
| Blue Earth Diagnostics | $226.84 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $203.07 | 2019-2025 | Provenge |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Yamada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.